Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: Results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313

Blood

Volumn 114, Issue 7, 2009, Pages 1429-1436

  Pulsipher, Michael A ^a   Boucher, Kenneth M ^b   Wall, Donna ^c   Frangoul, Haydar ^d   Duval, Michel ^e   Goyal, Rakesh K ^f   Shaw, Peter J ^g   Haight, Ann E ^h   Grimley, Michael ⁱ   Grupp, Stephan A ^j   Kletzel, Morris ^k   Kadota, Richard ^l  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c CANCERCARE MANITOBA   (Canada)

^d MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^e UNIVERSITY OF MONTREAL   (Canada)

^f CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^g CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Methodist Children's Hospital of South Texas   (United States)

^j CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^k CHILDREN'S MEMORIAL HOSPITAL   (United States)

^l RADY CHILDREN'S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOSPORIN; FLUDARABINE; THYMOCYTE ANTIBODY; MYELOABLATIVE AGENT;

ADOLESCENT; ADULT; ALLOTRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER THERAPY; CHILD; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; MALE; MORTALITY; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT OUTCOME; WHOLE BODY RADIATION; BLOOD DISEASE; DISEASE FREE SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; INFANT; METHODOLOGY; MULTICENTER STUDY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENT DISEASE; SURVIVAL RATE; TIME;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; MALE; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 70349337721     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-196303     Document Type: Article

References (52)

1. Alousi A, de Lima M. Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Clin Adv Hematol Oncol. 2007;5:560-570. (Pubitemid 47499915)
2. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia. 2006;20:1661-1672.
3. Rezvani AR, Storb R. Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies. Expert Opin Biol Ther. 2008;8:161-179. (Pubitemid 351233710)
4. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol. 2004;22:4872-4880. (Pubitemid 46638610)
5. Pulsipher MA, Levine JE, Hayashi RJ, et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant. 2005;35:361-367.
6. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer. 2006;46:422-433. (Pubitemid 43334647)
7. Pulsipher MA, Woolfrey A. Nonmyeloablative transplantation in children: current status and future prospects. Hematol Oncol Clin North Am. 2001;15:809-834. (Pubitemid 34026972)
8. Kletzel M, Jacobsohn D, Tse W, Duerst R. Reduced intensity transplants (RIT) in pediatrics: a review. Pediatr Transplant. 2005;9[Suppl 7]:63-70. (Pubitemid 41719269)
9. Satwani P, Cooper N, Rao K, Veys P, Amrolia P. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignan and nonmalignant diseases. Bone Marrow Transplant. 2008;41:173-182. (Pubitemid 351188915)
10. Yaniv I, Stein J. Reduced-intensity conditioning in children: a reappraisal in 2008. Bone Marrow Transplant. 2008;41[Suppl 2]:S18-S22.
11. Radich JP, Gooley T, Sanders JE, Anasetti C, Chauncey T, Appelbaum FR. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant. 2000;6:272-279.
12. Radich JP, Sanders JE, Buckner CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol. 1993;11:304-313.
13. Ringden O, Labopin M, Gorin NC, et al. The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed: Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2000;25:1053-1058.
14. Gassas A, Ishaqi MK, Afzal S, Dupuis A, Doyle J. Outcome of haematopoietic stem cell transplantation for paediatric acute lymphoblastic leukaemia in third complete remission: a vital role for graft-versus-host- disease/ graft-versus-leukaemia effect in survival. Br J Haematol. 2008;140:86-89. (Pubitemid 350233245)
15. Woolfrey AE, Anasetti C, Storer B, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood. 2002;99:2002-2008. (Pubitemid 34525481)
16. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
18. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706. (Pubitemid 29126745)
19. Klein J, Moeschberger M. Survival Analysis: Statistical Methods for Censored and Truncated Data. New York, NY: Springer-Verlag; 2003.
20. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912-2919. (Pubitemid 41510773)
21. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with non-myeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood. 2008;111:446-452.
22. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006;20:128-135.
23. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25:4246-4254.
24. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet. 2004;364:156-162. (Pubitemid 38891687)
25. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant. 2003;9:519-528. (Pubitemid 38351796)
26. Shenoy S, Grossman WJ, DiPersio J, et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005;35:345-352. (Pubitemid 40309479)
27. Cooper N, Rao K, Gilmour K, et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood. 2006;107:1233-1236. (Pubitemid 43156331)
28. Rao K, Amrolia PJ, Jones A, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood. 2005;105:879-885. (Pubitemid 40070779)
29. Veys P, Rao K, Amrolia P. Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioning. Bone Marrow Transplant. 2005;35[Suppl 1]:S45-S47. (Pubitemid 40613922)
30. Horn B, Baxter-Lowe LA, Englert L, et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant. 2006;37:263-269.
31. Burroughs LM, Storb R, Leisenring WM, et al. Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. Bone Marrow Transplant. 2007;40:633-642. (Pubitemid 47456477)
32. Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2005;36:215-225. (Pubitemid 41136293)
33. Krishnamurti L, Blazar BR, Wagner JE. Bone marrow transplantation without myeloablation for sickle cell disease. N Engl J Med. 2001;344:68. (Pubitemid 32064856)
34. Schleuning M, Stoetzer O, Waterhouse C, Schlemmer M, Ledderose G, Kolb HJ. Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease. Exp Hematol. 2002;30:7-10. (Pubitemid 34059212)
35. Del Toro G, Satwani P, Harrison L, et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant. 2004;33:613-622. (Pubitemid 38455923)
36. Gomez-Almaguer D, Ruiz-Arguelles GJ, Tarin-Arzaga Ldel C, et al. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol Blood Marrow Transplant. 2003;9:157-161.
37. Roman E, Cooney E, Harrison L, et al. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res. 2005;11[Suppl]:7164S-7170S. (Pubitemid 41428719)
38. Claviez A, Klingebiel T, Beyer J, et al. Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease. Ann Hematol. 2004;83:237-241. (Pubitemid 38443509)
39. Bradley MB, Satwani P, Baldinger L, et al. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant. 2007;40:621-631. (Pubitemid 47456476)
40. Meshinchi S, Leisenring WM, Carpenter PA, et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant. 2003;9:706-713. (Pubitemid 38145754)
41. Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2001;19:3675-3684. (Pubitemid 32786280)
42. Michallet M, Tanguy ML, Socie G, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol. 2000;108:400-407. (Pubitemid 30143659)
43. Eapen M, Giralt SA, Horowitz MM, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 2004;34:721-727. (Pubitemid 39406056)
44. Dey BR, McAfee S, Sackstein R, et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:604-612. (Pubitemid 33130593)
45. Shaw BE, Mufti GJ, Mackinnon S, et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant. 2008;42:783-789.
46. Baron F, Storb R, Storer BE, et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol. 2006;24:4150-4157. (Pubitemid 46622292)
47. Bader P, Hancock J, Kreyenberg H, et al. Minimal residual disease (MRD) status before allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia. 2002;16:1668-1672. (Pubitemid 35050095)
48. Olszewski M, Chou PM, Huang W, Tallman S, Kletzel M. Correlation of minimal residual disease by assessing Wilms tumor gene expression and engraftment by variable number of tandem repeats in children with leukemia posthematopoietic stem cell transplantation. Pediatr Dev Pathol. 2006;9:203-209. (Pubitemid 44140385)
49. Goulden N, Bader P, Van Der Velden V, et al. Minimal residual disease before stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;122:24-29. (Pubitemid 36819335)
50. Knechtli CJ, Goulden NJ, Hancock JP, et al. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol. 1998;102:860-871. (Pubitemid 28387073)
51. Knechtli CJ, Goulden NJ, Hancock JP, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood. 1998;92:4072-4079. (Pubitemid 28544322)
52. Levine JE, Barrett AJ, Zhang MJ, et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant. 2008;42:201-205.